ADVERTISEMENT

Metropolis Q3 Results Review — Lower Volumes Impact Performance; Centrum Broking Maintains 'Add' On The Stock

Going forward, management expects Metropolis' Ebitda margins dilution on account of Core acquisition, adds the brokerage.

<div class="paragraphs"><p>Metropolis Healthcare Ltd. delivered a miss on our estimates in Q3 FY25. (Photo Source: Company website)</p></div>
Metropolis Healthcare Ltd. delivered a miss on our estimates in Q3 FY25. (Photo Source: Company website)
Metropolis management reiterated its guidance revenue growth of 13-15% YoY which will largely be driven by volumes.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit